Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair

To examine the existing clinical evidence on the efficacy of prophylactic anticoagulation with direct factor Xa inhibitors versus low molecular weight heparins in the prevention of venous thromboembolism in patients who have undergone total hip or knee replacement or hip fracture repair.
To examine the existing clinical evidence on the efficacy of prophylactic anticoagulation with direct factor Xa inhibitors versus vitamin K antagonists, in the prevention of venous thromboembolism in patients who have undergone total hip or knee replacement or hip fracture repair.
To evaluate the existing clinical evidence on the risks including any adverse event (serious or not) of bleeding, skin necrosis, heparin-induced thrombocytopenia or hepatopathy associated with the analyzed therapies, in the prevention of venous thromboembolism in patients who have undergone total hip or knee replacement or hip fracture repair.

This is a protocol.

Health topics:

Heart & circulation > Deep vein thrombosis > Prevention: medical approaches

Heart & circulation > Pulmonary embolism > Prevention: medical approaches

Published:

29 June 2015

Authors:

Salazar CA, Malaga G, Malasquez G, Bernardo R

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Salazar CA, Malaga G, Malasquez G, Bernardo R. Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair. Cochrane Database of Systematic Reviews 2015, Issue 6. Art. No.: CD011762. DOI: 10.1002/14651858.CD011762